{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-013899","form_type":"8-K","ticker":"INBP","cik":"0001016504","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.615211+00:00","generated_at":"2026-06-15T03:20:05.853515+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Integrated BioPharma Q3 revenue down 16% YoY; net income falls to $16K from $0.8M","bullets":["Quarterly revenue $13.1M, down 16.2% from $15.6M in prior year.","Operating income $44K vs $1.0M; net income $16K ($0.00 EPS) vs $0.8M ($0.03 EPS).","Nine-month net loss $74K vs net income $2.3M in prior year.","Two largest customers fell from 91% to 88% of revenue; overstocking during pandemic cited as cause."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-013899","json":"https://secwatch.observer/filing/0001437749-23-013899.json","markdown":"https://secwatch.observer/filing/0001437749-23-013899.md","text":"https://secwatch.observer/filing/0001437749-23-013899.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1016504/000143774923013899/0001437749-23-013899-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1016504/000143774923013899/inbp20230509_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:20:05.853515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2c23511b374b76e55b97084de832494f3b85d255","claim":"INTEGRATED BIOPHARMA INC reported financial results for the three and nine months ended March 31, 2023.","evidence_excerpt":"On May 11, 2023, Integrated Biopharma, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1016504/000143774923013899/0001437749-23-013899-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}